XML 96 R70.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Collaborations and Other Arrangements (Details) $ / shares in Units, $ in Thousands, € in Millions |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 16, 2021 USD ($) $ / shares shares | Mar. 23, 2021 USD ($) | Feb. 01, 2021 USD ($) | Nov. 04, 2019 EUR (€) | May 02, 2019 | Mar. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Oct. 31, 2018 USD ($) item | Jan. 31, 2016 USD ($) | Mar. 31, 2025 USD ($) | Jun. 30, 2024 USD ($) | Dec. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2019 EUR (€) | Apr. 14, 2020 $ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  | $ 109,436 | $ 199,358 |  | $ 363,105 |  |  |
Share Price | $ / shares |  |  |  |  |  |  |  |  |  |  |  | $ 3.33 |  |  |  |  |  | $ 14.82
Upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |
Royalties due |  |  |  |  |  |  |  |  |  |  |  | 38,400 | 2,900 |  |  |  |  |
Vaccinex License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments to be made |  | $ 3,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products |  | $ 11,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bioeq IP AG |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial term of agreement |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of gross profits shared |  |  |  | 50.00% | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Bioeq IP AG | Licensed Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments | € |  |  |  | € 12.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payments related to FDA approval | € |  |  |  |  |  |  |  |  |  |  |  |  |  | € 2.5 |  |  |  |
Bioeq IP AG | Research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 11,100 | € 10.0 |
Adimab Development and Option Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum antibodies to be commercialized under commercialization option | item |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |
Technical milestone payments obligated to pay |  |  |  |  |  |  |  | $ 300 |  |  |  |  |  |  |  |  |  |
Period for payment of nominal research maintenance fee |  |  |  |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments to be made |  |  |  |  |  |  |  | $ 13,000 |  |  |  |  |  |  |  |  |  |
Maximum antibodies partially exercised under commercialization option | item |  |  |  |  |  |  |  | 10 |  |  |  |  |  |  |  |  |  |
Percentage of option fee to be paid on partial exercise of commercialization option |  |  |  |  |  |  |  | 65.00% |  |  |  |  |  |  |  |  |  |
Additional payment to be made |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |
Expiration term from the effective date without providing materials that pass quality control |  |  |  |  |  |  |  | 12 months |  |  |  |  |  |  |  |  |  |
Term of agreement |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |
Novartis Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of agreement |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Potential development milestones |  |  |  |  |  |  |  |  | $ 325,000 |  |  |  |  |  |  |  |  |
Sales milestones |  |  |  |  |  |  |  |  | $ 200,000 |  |  |  |  |  |  |  |  |
GSK Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales milestones |  |  |  |  |  |  | $ 485,000 |  |  |  |  |  |  |  |  |  |  |
Additional clinical milestones eligible to receive |  |  |  |  |  |  | 60,000 |  |  |  |  |  |  |  |  |  |  |
Regulatory milestones eligible to receive |  |  |  |  |  |  | $ 155,000 |  |  |  |  |  |  |  |  |  |  |
GSK Agreement | Surface |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments earned |  |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |  |  |
Junshi Biosciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement Fee |  |  |  |  |  |  |  |  |  |  |  | 35,000 |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  | 8,000 | 68,500 |  | $ 175,400 |  |  |
Unregistered shares | shares | 2,491,988 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share Price | $ / shares | $ 20.06 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate value | $ 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period before the company can sell, transfer or make any short sale of common stock (in years) | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value for the discount for lack of marketability (DLOM) |  |  |  |  |  |  |  |  |  |  |  | 9,000 |  |  |  |  |  |
Junshi Biosciences | Intangible assets, net and accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued milestone payment |  |  |  |  |  |  |  |  |  |  |  | 25,000 |  |  |  |  |  |
Junshi Biosciences | Accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  |  |  |  |  |  | 26,300 | 8,400 |  |  |  |  |
Junshi Biosciences | Accounts payable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  |  |  |  |  |  | $ 6,300 | $ 0 |  |  |  |  |
Junshi Biosciences | Licensed Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum paid amount for co-development activities (per licensed compound) |  |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Junshi Biosciences | Toripalimab (LOQTORZI) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, upfront amount paid |  |  | $ 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, royalty on net sales, percentage |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones |  |  | $ 380,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CHS-006 anti-TIGIT antibody |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement Fee |  |  | $ 35,000 |  |  | 35,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, royalty on net sales for each exercised option, percentage |  |  | 18.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program |  |  | $ 85,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CHS-006 anti-TIGIT antibody | Anti-TIGIT Antibody and IL-2 cytokine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program |  |  |  |  |  | $ 170,000 |  |  |  |  |  |  |  |  |  |  |  |
Scenario, Plan | Junshi Biosciences | Toripalimab (LOQTORZI) | Intangible assets, net and accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payment |  |  |  |  |  |  |  |  |  | $ 12,500 | $ 12,500 |  |  |  |  |  |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. + References No definition available. + Details
Name: | chrs_AccruedMilestonePayment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Additional milestone payments upon achievement of certain development and regulatory milestones. + References No definition available. + Details
Name: | chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Additional milestone payments upon achievement of with subject to FDA approval + References No definition available. + Details
Name: | chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents co-development, regulatory and technology transfer costs. + References No definition available. + Details
Name: | chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of additional clinical milestones eligible to receive + References No definition available. + Details
Name: | chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional payment to be made + References No definition available. + Details
Name: | chrs_CollaborationAgreementAdditionalPaymentToBeMade
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expiration term from the effective date without providing materials that pass quality control + References No definition available. + Details
Name: | chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum aggregate milestone payments to be made + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone payments earned + References No definition available. + Details
Name: | chrs_CollaborationAgreementMilestonePaymentsEarned
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of option exercise fee per program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of royalty on net sales under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of royalty on net sales for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for payment of nominal research maintenance fee + References No definition available. + Details
Name: | chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of regulatory milestones eligible to receive + References No definition available. + Details
Name: | chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Technical milestone payments obligated to pay + References No definition available. + Details
Name: | chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Term of agreement + References No definition available. + Details
Name: | chrs_CollaborationAgreementTerm
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents costs associated to a collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the fair value for the discount for lack of marketability (DLOM). + References No definition available. + Details
Name: | chrs_FairValueForDiscountForLackOfMarketability
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Initial term of agreement. + References No definition available. + Details
Name: | chrs_InitialTermOfAgreement
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum paid amount for co-development activities. + References No definition available. + Details
Name: | chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum antibodies partially exercised under commercialization option + References No definition available. + Details
Name: | chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum antibodies to be commercialized under commercialization option + References No definition available. + Details
Name: | chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition percentage of profit shared. + References No definition available. + Details
Name: | chrs_PercentageOfGrossProfitsOnSales
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of option fee to be paid on partial exercise of commercialization option + References No definition available. + Details
Name: | chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of potential development milestones entitled. + References No definition available. + Details
Name: | chrs_PotentialDevelopmentMilestonesEntitled
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the period before the company can sell, transfer or make any short sale of common stock. + References No definition available. + Details
Name: | chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of regulatory milestones eligible to pay. + References No definition available. + Details
Name: | chrs_RegulatoryMilestonesEligibleToPay
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of sales milestones entitled. + References No definition available. + Details
Name: | chrs_SalesMilestonesEntitled
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement. + References No definition available. + Details
Name: | chrs_StockPurchaseAgreementSharesAgreedToBeIssued
Namespace Prefix: | chrs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement. + References No definition available. + Details
Name: | chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents upfront and milestone payments. + References No definition available. + Details
Name: | chrs_UpfrontAndMilestonePayment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_NovartisAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=chrs_SurfaceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_ToripalimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_Chs006AntiTigitAntibodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |